Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EPIX ESSA Pharma	$1.88 +0.5%	$1.71	$1.40 ▼ $7.88	$83.01M	1.56	369,136 shs	328,689 shs
HGEN Humanigen		$0.00	$0.00 ▼ $0.24	$24K	-1.04	3.26 million shs	2.06 million shs
MNKD MannKind	$3.76 -3.6%	$4.02	$3.51 ▼ $7.63	$1.19B	0.96	2.43 million shs	2.31 million shs
PRTA Prothena	$6.26 -3.2%	$6.02	$4.32 ▼ $25.42	$348.26M	0.01	806,224 shs	788,135 shs
VERU Veru	$0.60 -2.8%	$0.58	$0.45 ▼ $1.42	$89.97M	-0.75	1.93 million shs	986,778 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EPIX ESSA Pharma	+0.54%	+6.86%	+10.65%	+4.47%	-67.19%
HGEN Humanigen	0.00%	0.00%	0.00%	0.00%	0.00%
MNKD MannKind	-1.52%	+2.63%	+4.00%	-14.10%	-32.76%
PRTA Prothena	+2.37%	-1.52%	+13.51%	-29.67%	-72.90%
VERU Veru	+2.30%	+5.25%	+5.77%	+14.90%	-39.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EPIX ESSA Pharma	1.0211 of 5 stars	1.0	2.0	0.0	0.0	2.5	2.5	1.3
HGEN Humanigen	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	2.6384 of 5 stars	3.6	0.0	0.0	0.0	2.2	1.7	1.9
PRTA Prothena	3.6168 of 5 stars	4.2	4.0	0.0	0.0	1.6	1.7	1.3
VERU Veru	2.5363 of 5 stars	3.5	4.0	0.0	0.0	2.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EPIX ESSA Pharma	2.00	Hold	$2.00	6.38% Upside
HGEN Humanigen	0.00	N/A	N/A	N/A
MNKD MannKind	3.25	Buy	$10.14	169.76% Upside
PRTA Prothena	2.33	Hold	$31.50	403.19% Upside
VERU Veru	3.00	Buy	$4.00	570.58% Upside

Current Analyst Ratings Breakdown

Latest EPIX, PRTA, VERU, HGEN, and MNKD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	MNKD MannKind	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$9.00
6/20/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
5/28/2025	PRTA Prothena	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underperform
5/27/2025	PRTA Prothena	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$110.00 ➝ $81.00
5/27/2025	PRTA Prothena	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$78.00 ➝ $29.00
5/27/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
5/27/2025	PRTA Prothena	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$6.00
5/27/2025	PRTA Prothena	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/27/2025	PRTA Prothena	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $14.00
5/27/2025	PRTA Prothena	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $18.00
5/13/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	$2.81 per share	N/A
HGEN Humanigen	$1.70M	0.00	N/A	N/A	($0.45) per share	0.00
MNKD MannKind	$285.50M	4.00	$0.13 per share	28.10	($0.29) per share	-12.97
PRTA Prothena	$135.16M	2.49	N/A	N/A	$9.05 per share	0.69
VERU Veru	$16.89M	5.18	N/A	N/A	$0.22 per share	2.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EPIX ESSA Pharma	-$28.54M	-$0.63	0.00	N/A	N/A	N/A	-23.48%	-22.86%	8/4/2025 (Estimated)
HGEN Humanigen	-$70.73M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	$27.59M	$0.10	37.60	16.35	N/A	10.12%	-32.41%	10.85%	8/6/2025 (Estimated)
PRTA Prothena	-$122.31M	-$2.08	0.00	N/A	N/A	-79.94%	-21.61%	-19.32%	8/6/2025 (Estimated)
VERU Veru	-$37.80M	-$0.24	0.00	N/A	N/A	N/A	-128.51%	-76.51%	8/6/2025 (Estimated)

Latest EPIX, PRTA, VERU, HGEN, and MNKD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PRTA Prothena	-$1.06	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q3 2025	VERU Veru	-$0.06	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	MNKD MannKind	$0.04	N/A	N/A	N/A	$77.82 million	N/A
8/4/2025	Q3 2025	EPIX ESSA Pharma	-$0.2430	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q2 2025	EPIX ESSA Pharma	-$0.19	-$0.14	+$0.05	-$0.14	N/A	N/A
5/8/2025	Q1 2025	MNKD MannKind	$0.03	$0.04	+$0.01	$0.04	$75.86 million	$78.35 million
5/8/2025	Q1 2025	PRTA Prothena	-$0.92	-$1.12	-$0.20	-$1.12	$8.18 million	$2.83 million
5/8/2025	Q2 2025	VERU Veru	-$0.06	-$0.05	+$0.01	-$0.05	$0.73 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	N/A
HGEN Humanigen	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A
VERU Veru	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EPIX ESSA Pharma	N/A	67.15	67.15
HGEN Humanigen	N/A	N/A	N/A
MNKD MannKind	N/A	2.36	2.11
PRTA Prothena	N/A	9.00	9.00
VERU Veru	N/A	3.80	3.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EPIX ESSA Pharma	75.12%
HGEN Humanigen	4.55%
MNKD MannKind	49.55%
PRTA Prothena	97.08%
VERU Veru	47.16%

Insider Ownership

Company	Insider Ownership
EPIX ESSA Pharma	15.50%
HGEN Humanigen	21.70%
MNKD MannKind	2.70%
PRTA Prothena	9.20%
VERU Veru	15.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EPIX ESSA Pharma	50	44.39 million	37.51 million	Optionable
HGEN Humanigen	6	119.08 million	93.24 million	No Data
MNKD MannKind	400	303.93 million	295.73 million	Optionable
PRTA Prothena	130	53.83 million	48.88 million	Optionable
VERU Veru	230	146.58 million	124.30 million	Optionable

EPIX, PRTA, VERU, HGEN, and MNKD Headlines

Recent News About These Companies

Veru survey highlights muscle loss concerns among GLP-1 users, as lean mass-preserving med plows ahead

July 16 at 8:53 PM | fiercepharma.comF

Veru (NASDAQ:VERU) Share Price Passes Above 200 Day Moving Average - Time to Sell?

July 16 at 5:11 AM | marketbeat.com

Veru And Two Other Penny Stocks To Consider

June 26, 2025 | finance.yahoo.com

Veru Inc (FMW.DU)

June 26, 2025 | nz.finance.yahoo.com

Veru reports positive results for enobosarm in weight management study

June 26, 2025 | uk.investing.com

Why Veru Inc. Is Rising In Pre-market? - Nasdaq

June 26, 2025 | nasdaq.com

Veru (NASDAQ:VERU) Stock Price Crosses Below 200-Day Moving Average - Here's What Happened

June 25, 2025 | marketbeat.com

One Veru Insider Raised Stake By 150% In Previous Year

June 22, 2025 | finance.yahoo.com

Scholar Rock drug preserves muscle in obesity trial

June 18, 2025 | yahoo.com

Veru Inc. to Engage with Investors at BTIG Obesity Health Forum on June 18, 2025

June 11, 2025 | quiverquant.comQ

Veru to Participate in the Virtual BTIG Obesity Health Forum

June 11, 2025 | globenewswire.com

Beyond Meat, Plby among consumer staple names set to join Russell Microcap Index, Veru, Vital Farms to leave

May 30, 2025 | seekingalpha.com

Veru’s obesity drug roughly as safe as Wegovy; Keros’ board fight

May 28, 2025 | endpts.comE

Muscle-sparing obesity drug safe for Phase 3 trial, Veru says

May 28, 2025 | yahoo.com

Veru Inc. Announce Positive Topline Safety Data from Phase 2b QUALITY Study of Enobosarm Combined with Semaglutide

May 28, 2025 | quiverquant.comQ

Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone

May 28, 2025 | globenewswire.com

Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom

May 26, 2025 | seekingalpha.com

Youngsters at Dunstable school hear about the dangers of knife crime

May 22, 2025 | msn.com

Veru Inc.: Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

May 8, 2025 | finanznachrichten.de

Veru signals Q3 2025 regulatory clarity for enobosarm Phase 3 trial

May 8, 2025 | msn.com

Veru Inc. (VERU) Q2 2025 Earnings Call Transcript

May 8, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPIX, PRTA, VERU, HGEN, and MNKD Company Descriptions

ESSA Pharma NASDAQ:EPIX

$1.88 +0.01 (+0.53%)

Closing price 04:00 PM Eastern

Extended Trading

$1.87 -0.01 (-0.53%)

As of 05:51 PM Eastern

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Humanigen NASDAQ:HGEN

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey. On January 3, 2024, Humanigen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

MannKind NASDAQ:MNKD

$3.76 -0.14 (-3.59%)

Closing price 04:00 PM Eastern

Extended Trading

$3.80 +0.04 (+1.04%)

As of 07:58 PM Eastern

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Prothena NASDAQ:PRTA

$6.26 -0.21 (-3.25%)

Closing price 04:00 PM Eastern

Extended Trading

$6.64 +0.38 (+6.07%)

As of 07:33 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Veru NASDAQ:VERU

$0.60 -0.02 (-2.82%)

Closing price 04:00 PM Eastern

Extended Trading

$0.61 +0.01 (+2.43%)

As of 06:54 PM Eastern

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time